Group 1 - The core technology of "uniform particle size drug-loaded microspheres" developed by Suzhou Heng Rui Medical Devices Co., Ltd. has received patent authorization from the United States Patent and Trademark Office (USPTO) [1] - Liver cancer ranks sixth in incidence and third in mortality globally, with approximately 72% of cases occurring in Asia, particularly in China, which accounts for about 50% of global cases [1] - The early diagnosis rate for liver cancer is less than 30%, and the five-year survival rate for patients in mid to late stages is only 12%, with a postoperative recurrence rate as high as 50%-70% [1] Group 2 - The Ministry of Industry and Information Technology's "14th Five-Year Plan for the Development of the Medical Equipment Industry" emphasizes the localization of high-end interventional devices, aiming for domestic medical device performance to reach international standards by 2025 [2] - The patent authorization represents a significant response to national medical device strategies, primarily benefiting domestic liver cancer patients in need of better treatment options [2] - Heng Rui Medical's breakthrough technology is expected to lower the treatment threshold for D-TACE, facilitating its widespread application in domestic hospitals and reducing the need for patients to seek expensive imported materials [2] Group 3 - The core value of the patent authorization lies in overcoming the global challenge of "particle size uniformity" in drug-loaded microspheres, establishing a new global precision standard based on Chinese standards [2] - Heng Rui Medical aims to leverage this patent authorization to deepen its focus on the precision embolization field and accelerate the implementation of domestic innovative results in clinical settings [2] - The company seeks to transform cutting-edge technology into accessible treatment options for Chinese patients while providing superior "Chinese solutions" for global cancer patients [2]

Core Viewpoint - The recent patent granted to Heng Rui Medical for its "Uniform Particle Size Drug-loaded Microspheres" technology marks a significant milestone for Chinese medical device innovation, enabling the company to break into the global market and enhance treatment options for liver cancer patients in China [1][2][5] Group 1: Patent Significance - The patent represents a breakthrough in drug-loaded microsphere technology, allowing for the first time a Chinese company to establish a foothold in the core technology and materials sector of this field [1][2] - This achievement is a key step towards the goal of "high-end medical equipment domestic substitution" as outlined in China's 14th Five-Year Plan [2][5] Group 2: Impact on Liver Cancer Treatment - The technology is expected to significantly reduce the cost and improve the accessibility of D-TACE (Drug-loaded Transarterial Chemoembolization) treatment for liver cancer patients in China, who have been facing high costs associated with imported materials [2][4] - The patent addresses the critical issue of low early diagnosis rates and high recurrence rates in liver cancer treatment, which currently sees a 5-year survival rate of only 12% for late-stage patients [1] Group 3: Technological Advancements - Heng Rui Medical's patented technology achieves a remarkable control of particle size variation (CV value) at below 5%, setting a new global standard for microsphere manufacturing precision [3][4] - The innovation allows for a shift from empirical to personalized precision embolization in D-TACE, laying the groundwork for future integration with other innovative treatment modalities [3] Group 4: Market Dynamics - The patent is expected to disrupt the existing market dominated by foreign companies, which have historically controlled 90% of the drug-loaded microsphere market through patent barriers [4] - With the release of domestic high-quality microsphere production, the company aims to accelerate the process of import substitution and enhance the security of the domestic supply chain [4]